Therapy optimization remains an important challenge in the treatment of advanced non‐
small cell lung cancer (NSCLC). We investigated tumor size (sum of the longest diameters …

3035 Background: Progression of cancer is often associated with biomarkers of cancer
inflammation, cachexia, and increased protein catabolism. Anti-PD1 and PD-L1 therapy …

Simple Summary This prospective exploratory study suggested the feasibility of circulating
tumor cells (CTCs) and peripheral blood cells (PBCs), especially platelets, as predictive …

Backgrounds The PACIFIC trial established durvalumab consolidation therapy after
concurrent chemoradiotherapy (CCRT) as the standard treatment for locally advanced non …

Sustained elevation in neutrophil‐to‐lymphocyte ratio (NLR) after initial chemoradiotherapy
(CRT) has been shown to correlate with worse prognosis in a number of solid organ …

Background Elevated pre-treatment neutrophil-to-lymphocyte ratio (NLR) may reflect
immune dysfunction and is negatively prognostic in cancer patients treated with …

Four non‐small‐cell lung cancer (NSCLC) registration trials were utilized to develop models
linking survival to risk factors and changes in tumor size during treatment. The purpose was …

Background: Selecting patients who potentially benefit from immune checkpoint inhibitors
(ICIs) is critical. Programmed death ligand-1 (PD-L1) protein immunohistochemical …

2566 Background: Durvalumab is a human monoclonal antibody that binds to PD-L1 and
blocks its interaction with PD-1 and CD80. The objectives of this analysis were to develop a …

Aim To investigate the impact of PD-L1 expression status on consolidative durvalumab
efficacy and safety in stage III NSCLC patients. Methods This retrospective, ethics board …